225 related articles for article (PubMed ID: 21033210)
1. Tumor lysis syndrome after sorafenib for hepatocellular carcinoma: a case report.
Shiozawa K; Watanabe M; Takenaka H; Nagai H; Ishii K; Sakai K; Sumino Y
Hepatogastroenterology; 2010; 57(101):688-90. PubMed ID: 21033210
[TBL] [Abstract][Full Text] [Related]
2. All that glitters: sorafenib.
Abbass K; Dewani S; Markert R; Kaplon MK; Baumann MA
Intern Med; 2011; 50(7):797. PubMed ID: 21467725
[No Abstract] [Full Text] [Related]
3. Sorafenib induced tumor lysis syndrome in an advanced hepatocellular carcinoma patient.
Huang WS; Yang CH
World J Gastroenterol; 2009 Sep; 15(35):4464-6. PubMed ID: 19764104
[TBL] [Abstract][Full Text] [Related]
4. A patient with advanced hepatocellular carcinoma treated with sorafenib tosylate showed massive tumor lysis with avoidance of tumor lysis syndrome.
Joshita S; Yoshizawa K; Sano K; Kobayashi S; Sekiguchi T; Morita S; Kamijo A; Komatsu M; Umemura T; Ichijo T; Matsumoto A; Tanaka E
Intern Med; 2010; 49(11):991-4. PubMed ID: 20519814
[TBL] [Abstract][Full Text] [Related]
5. Long-term results of sorafenib in advanced-stage hepatocellular carcinoma: what can we learn from routine clinical practice?
Sacco R; Bargellini I; Ginanni B; Bertini M; Faggioni L; Federici G; Romano A; Bertoni M; Metrangolo S; Altomare E; Parisi G; Tumino E; Scaramuzzino A; Bresci G; Bartolozzi C
Expert Rev Anticancer Ther; 2012 Jul; 12(7):869-75. PubMed ID: 22845401
[TBL] [Abstract][Full Text] [Related]
6. Tolerance and outcome of patients with unresectable hepatocellular carcinoma treated with sorafenib.
Ozenne V; Paradis V; Pernot S; Castelnau C; Vullierme MP; Bouattour M; Valla D; Farges O; Degos F
Eur J Gastroenterol Hepatol; 2010 Sep; 22(9):1106-10. PubMed ID: 20300004
[TBL] [Abstract][Full Text] [Related]
7. Low-dose steroid-induced tumor lysis syndrome in a hepatocellular carcinoma patient.
Kim JO; Jun DW; Tae HJ; Lee KN; Lee HL; Lee OY; Choi HS; Yoon BC; Hahm JS
Clin Mol Hepatol; 2015 Mar; 21(1):85-8. PubMed ID: 25834806
[TBL] [Abstract][Full Text] [Related]
8. Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy.
Iavarone M; Cabibbo G; Piscaglia F; Zavaglia C; Grieco A; Villa E; Cammà C; Colombo M;
Hepatology; 2011 Dec; 54(6):2055-63. PubMed ID: 21898496
[TBL] [Abstract][Full Text] [Related]
9. Safety and effectiveness of sorafenib in patients with hepatocellular carcinoma in clinical practice.
Di Costanzo GG; Tortora R; Iodice L; Lanza AG; Lampasi F; Tartaglione MT; Picciotto FP; Mattera S; De Luca M
Dig Liver Dis; 2012 Sep; 44(9):788-92. PubMed ID: 22579445
[TBL] [Abstract][Full Text] [Related]
10. Sorafenib, risk of bleeding and spontaneous rupture of hepatocellular carcinoma. A clinical case.
Rombolà F; Caravetta A; Mollo F; Spinoso A; Peluso L; Guarino R
Acta Medica (Hradec Kralove); 2011; 54(4):177-9. PubMed ID: 22283115
[TBL] [Abstract][Full Text] [Related]
11. Acute hepatitis in a patient with cirrhosis and hepatocellular carcinoma treated with sorafenib.
Llanos L; Bellot P; Zapater P; Pérez-Mateo M; Such J
Am J Gastroenterol; 2009 Jan; 104(1):257-8. PubMed ID: 19098892
[No Abstract] [Full Text] [Related]
12. Computed tomography findings of sorafenib-treated hepatic tumors in patients with advanced hepatocellular carcinoma.
Kim MJ; Choi JI; Lee JS; Park JW
J Gastroenterol Hepatol; 2011 Jul; 26(7):1201-6. PubMed ID: 21371120
[TBL] [Abstract][Full Text] [Related]
13. [Gastrointestinal hemorrhage associated with concurrent use of sorafenib and warfarin for hepatocellular carcinoma].
Shiozawa K; Watanabe M; Hirano N; Wakui N; Kikuchi Y; Hara F; Ishii K; Iida K; Sumino Y
Gan To Kagaku Ryoho; 2011 Oct; 38(10):1713-5. PubMed ID: 21996974
[TBL] [Abstract][Full Text] [Related]
14. A long-lasting response to sorafenib treatment in an advanced hepatocellular carcinoma patient.
Di Lorenzo G; Imbimbo M; Leopardo D; Marciano R; Federico P; Buonerba C; Salvatore B; Marinelli A; Palmieri G
Int J Immunopathol Pharmacol; 2010; 23(3):951-4. PubMed ID: 20943068
[TBL] [Abstract][Full Text] [Related]
15. Sunitinib in patients with advanced hepatocellular carcinoma after progression under sorafenib treatment.
Wörns MA; Schuchmann M; Düber C; Otto G; Galle PR; Weinmann A
Oncology; 2010; 79(1-2):85-92. PubMed ID: 21071995
[TBL] [Abstract][Full Text] [Related]
16. Splenic infarction associated with sorafenib use in a hepatocellular carcinoma patient.
Kim SO; Han SY; Baek YH; Lee SW; Han JS; Kim BG; Cho JH; Nam KJ
World J Gastroenterol; 2011 Jan; 17(2):267-70. PubMed ID: 21246003
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Cheng AL; Kang YK; Chen Z; Tsao CJ; Qin S; Kim JS; Luo R; Feng J; Ye S; Yang TS; Xu J; Sun Y; Liang H; Liu J; Wang J; Tak WY; Pan H; Burock K; Zou J; Voliotis D; Guan Z
Lancet Oncol; 2009 Jan; 10(1):25-34. PubMed ID: 19095497
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis.
Wörns MA; Weinmann A; Pfingst K; Schulte-Sasse C; Messow CM; Schulze-Bergkamen H; Teufel A; Schuchmann M; Kanzler S; Düber C; Otto G; Galle PR
J Clin Gastroenterol; 2009; 43(5):489-95. PubMed ID: 19247201
[TBL] [Abstract][Full Text] [Related]
19. Sorafenib for the treatment of advanced hepatocellular carcinoma.
Connock M; Round J; Bayliss S; Tubeuf S; Greenheld W; Moore D
Health Technol Assess; 2010 May; 14 Suppl 1():17-21. PubMed ID: 20507799
[TBL] [Abstract][Full Text] [Related]
20. Probable sorafenib-induced reversible encephalopathy in a patient with hepatocellular carcinoma.
Dogan E; Aksoy S; Arslan C; Dede DS; Altundag K
Med Oncol; 2010 Dec; 27(4):1436-7. PubMed ID: 20012235
[No Abstract] [Full Text] [Related]
[Next] [New Search]
